Drug-drug interactions<unk>  does not interfere with the plasma concentration of drugs that are also metabolized by the same enzymes (i.e. CYP2C19) that it is metabolized by. Therefore, it is not expected to react with CYP2C19 substrates like theophylline, warfarin, diazepam, and phenytoin. However, the acid-suppression effects of<unk> , like other PPIs, may interfere with the absorption of drugs that require acid, such as ketoconazole and digoxin. There is some evidence that omeprazole and esomeprazole, two medications in the same class as<unk> , can disturb the conversion of an anticoagulant medication called clopidogrel to its active metabolite. However, because this is thought to be mediated by the effect of omeprazole and esomeprazole on CYP2C19, the enzyme that activates clopidogrel, this drug interaction is not expected to occur as strongly with<unk> . However, whether the effect of omeprazole and esomeprazole on clopidogrel's metabolism actually leads to poor clinical outcomes is still a matter of intense debate among healthcare professionals. Clinically serious drug-drug interactions may involve the acid-suppression effects of<unk> . For example,<unk>  should not be used concomitantly with rilpivirine, an anti-HIV therapy, which requires acid for absorption. Lowered plasma concentrations of rilpivirine could lead to progression of HIV infection. Other drugs that require acid for absorption include antifungal drugs like ketoconazole and itraconazole, digoxin, iron, mycophenolate, and tyrosine kinase inhibitors like erlotinib, dasatinib, and nilotinib. There is no clinically relevant drug interaction between<unk>  and antacids. Food-drug interactions Food does not affect the amount of<unk>  that enters the body, but it does delay its onset of effect by about 1.7 hours.
Rabeprazole
Esomeprazole
Lansoprazole
Omeprazole
Dexlansoprazole
Tenatoprazole
Pantoprazole
Cimetidine